A Chance to Reflect and Look Forward
Highlighting a year of conference coverage for ACT.
Over the past few weeks, signs of 2023 coming to an end are aplenty; the temperatures have fallen, and holidays are beginning to appear more frequently on the calendar. I’m sure I’m not alone in feeling that the end of each year serves as a good time to reflect on the previous 12 months. For Applied Clinical Trials, there have been many bright spots throughout 2023. One in particular I’d like to highlight here is our conference coverage—a pillar of our many brands at MJH Life Sciences®. ACT was front and center at several of this year's largest industry conferences, including the Summit for Clinical Ops Executives (SCOPE) North America, SCOPE Europe (see our executive roundtable from the event here), DPHARM, and the DIA Annual Meeting. Our editors did a fantastic job in providing timely coverage of breakout sessions and speaking with industry leaders for video interviews. All of the content can be found here on our website:
www.appliedclinicaltrialsonline.com/latest-conference. We look forward to continuing our coverage of these events in 2024.
Not to be overlooked, of course, are present happenings. For this December issue of ACT, we focus on novel clinical trial designs. From basket trials, to using real-world evidence (RWE), and master protocols, there are many new elements to trial design. We explore some of these design approaches and how regulatory authorities are moving the needle on their acceptance.
Our first feature examines the benefits of early protocol assessment in boosting patient centricity. For example, with so many new design elements in the fold, getting ahead of potential pitfalls can greatly reduce patient burden while expanding opportunities to apply clinical data on a wider scale.
Following is a feature looking at innovation in clinical trials for chimeric antigen receptor (CAR) T-cell therapies. These products have steadily demonstrated positive results for oncology patients in recent years. The article focuses on next-step, digitally driven pursuits for CAR T-cell trials and how this area can be advanced further. Our final December feature discusses strategies for implementing digital protocols and ways to streamline processes such as content reuse, workflow animation, and study design.
As always, thank you for reading.
Mike Hennessy Jr, president and CEO, MJH Life Sciences®
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
